Fuchs Endothelial Dystrophy — Stages, Symptoms and Treatment

Fuchs endothelial corneal dystrophy is a progressive hereditary condition affecting the innermost layer of the cornea. It is one of the most common indications for corneal transplantation in Australia and is a condition I see regularly in my practice at Northern Eye Consultants in Bundoora. The condition follows a predictable course through distinct stages, and understanding where a patient sits on that spectrum determines whether watchful waiting, conservative management, or surgery is the right approach.

The corneal endothelium and why it matters

The corneal endothelium is a single layer of cells lining the inner surface of the cornea. Its primary function is to pump fluid out of the corneal stroma, keeping the cornea in a slightly dehydrated state that is essential for optical clarity. Healthy eyes contain approximately 3,000 to 4,000 endothelial cells per square millimetre. In Fuchs dystrophy, these cells die at an accelerated rate; when density falls below roughly 500 cells per square millimetre, the remaining cells can no longer maintain adequate pumping and the cornea begins to swell and cloud.

The cornea must remain in a slightly dehydrated state to remain optically clear. This dehydration is maintained by the corneal endothelium, a single layer of hexagonal cells lining the inner surface of the cornea whose primary function is to pump fluid out of the corneal stroma. Healthy eyes are born with approximately 3,000 to 4,000 endothelial cells per square millimetre. This density declines slowly with normal ageing, but problems arise only when cell density falls below approximately 500 cells per square millimetre, at which point the remaining cells cannot maintain adequate fluid pumping and the cornea begins to swell.

Early stage — guttae, no symptoms

In the early stage of Fuchs dystrophy, abnormal collagen deposits called guttae appear on Descemet membrane, visible under slit-lamp examination as tiny excrescences on the inner corneal surface. Endothelial cell density remains sufficient to maintain corneal clarity and most patients have no visual symptoms at this stage. The condition is commonly detected incidentally during a routine eye examination or pre-operative cataract assessment. The early stage can persist for many years without meaningful progression.

In Fuchs dystrophy, endothelial cells are dysfunctional and die at an accelerated rate. The dying cells leave behind abnormal collagen deposits called guttae on Descemet membrane, the thin basement membrane that lines the inner cornea. These tiny excrescences are visible under slit-lamp examination and are the earliest diagnostic finding of the condition.

In the early stage, guttae are present centrally or paracentrally but endothelial cell density remains sufficient to maintain corneal clarity. Most patients have no visual symptoms; the condition is detected incidentally during a routine eye examination or pre-operative cataract assessment. The early stage can persist for many years without meaningful progression.

Intermediate stage — morning blur and glare

The hallmark of intermediate Fuchs dystrophy is vision that is blurred or hazy on waking and partially clears through the day. This diurnal pattern occurs because the cornea accumulates fluid overnight when the eye is closed and tear evaporation is reduced. As the eye opens and remains exposed through the day, some fluid evaporates and vision improves. Glare, halos around lights, and reduced contrast sensitivity are common at this stage. Conservative measures, including hypertonic saline drops and a morning hairdryer routine, can provide meaningful symptom relief.

As endothelial cell loss continues and guttae spread across the central cornea, the pumping capacity of the endothelium begins to fail. In the intermediate stage, the cornea accumulates fluid overnight while the eye is closed and tear evaporation is reduced. On waking, the cornea is maximally swollen and vision is blurred or hazy. As the day progresses and the eye remains open, some fluid evaporates through the tear film and vision partially clears; the diurnal pattern of morning blur improving through the day is the hallmark presentation of intermediate Fuchs dystrophy.

Glare, halos around lights, and reduced contrast sensitivity are common at this stage. Bright sunlight and oncoming headlights at night are frequently reported as troublesome. Conservative measures, including hypertonic saline drops and a morning hairdryer routine, can provide meaningful symptom relief at this stage.

Advanced stage — persistent oedema and pain

In the advanced stage of Fuchs dystrophy, the endothelium can no longer maintain any meaningful corneal dehydration. Vision remains blurred throughout the day regardless of the time since waking, and corneal thickness is significantly elevated on measurement. In severe cases, fluid blisters (bullae) form on the epithelial surface and can rupture, exposing corneal nerve endings and causing acute pain and a foreign body sensation. Surgical treatment is generally required once the condition reaches this stage.

In advanced Fuchs dystrophy, the morning improvement disappears as the endothelium can no longer maintain any meaningful dehydration of the stroma. Vision remains blurred throughout the day regardless of the time since waking. Corneal thickness is significantly elevated on measurement. In severe cases, fluid blisters (bullae) form on the epithelial surface and can rupture, exposing corneal nerve endings and causing acute pain and a foreign body sensation. Surgical treatment is generally required at this stage.

Assessment and diagnosis

Fuchs dystrophy is diagnosed by slit-lamp examination, which reveals the characteristic guttae on Descemet membrane. Three additional assessments are used to quantify severity and guide management: specular microscopy to measure endothelial cell density and cell morphology; Pentacam imaging to provide precise corneal thickness (pachymetry) maps and track progression objectively over time; and anterior segment OCT, which can detect early oedema before it becomes clinically apparent. Serial Pentacam measurements showing rising central corneal thickness are a reliable marker of disease progression.

Diagnosis is established by slit-lamp examination, which reveals the characteristic guttae. Several additional assessments are used to quantify severity and guide management:

• Specular microscopy — measures endothelial cell density along with cell size variability (polymegethism) and shape irregularity (pleomorphism). This is the most direct measure of endothelial reserve and is essential before any intraocular surgery in an eye with Fuchs changes.
• Pentacam imaging — a rotating Scheimpflug camera providing anterior segment tomography, including precise corneal thickness (pachymetry) maps across the full corneal surface. Rising central corneal thickness on serial Pentacam measurements is a reliable and objective marker of disease progression, even before symptoms develop.
• Anterior segment OCT — can visualise Descemet membrane changes and detect intraepithelial or subepithelial oedema before it is clinically apparent on examination.

When is treatment needed?

Many patients with Fuchs dystrophy are monitored for years without requiring intervention. Treatment becomes appropriate when vision deterioration affects daily activities, when endothelial cell counts suggest the cornea will not safely tolerate planned cataract surgery, or when corneal oedema is advanced enough that conservative measures, including hypertonic saline drops and a morning hairdryer routine, no longer provide acceptable vision. The timing of surgery and whether it is combined with cataract extraction is a clinical judgement based on each patient's corneal status, visual needs, and lens status.

Many patients are monitored without intervention for years. Surgical treatment is indicated when vision deterioration is affecting daily activities, when endothelial cell counts suggest the cornea will not safely tolerate planned cataract surgery, or when oedema is advanced enough that conservative measures no longer provide acceptable vision. The timing of surgery, and whether it is combined with cataract extraction or performed as an isolated corneal procedure, is a clinical judgement based on each patient's corneal status, visual needs, and lens status.

DMEK — the surgical treatment of choice

DMEK (Descemet Membrane Endothelial Keratoplasty) is the preferred surgical treatment for most patients with Fuchs dystrophy requiring corneal transplantation. Only the diseased Descemet membrane and endothelium, a graft approximately 10 to 15 microns thick, are replaced, while the patient's own healthy anterior cornea remains intact. This tissue-selective approach provides better visual outcomes, faster recovery, and a significantly lower rejection rate than older techniques such as DSAEK or full-thickness penetrating keratoplasty. Most patients achieve functional vision within four to six weeks of surgery.

For most patients with Fuchs dystrophy requiring surgery, DMEK (Descemet Membrane Endothelial Keratoplasty) is now the preferred procedure. DMEK replaces only the diseased Descemet membrane and endothelium, a graft approximately 10 to 15 microns thick, while preserving the patient's own healthy anterior cornea. This tissue-selective approach provides better visual outcomes, faster recovery, and a significantly lower rejection rate than earlier techniques such as DSAEK or full-thickness penetrating keratoplasty.

Most patients achieve functional vision within four to six weeks, with the majority of improvement complete by three months. For patients who also have a visually significant cataract, combined DMEK and cataract surgery in a single procedure shortens the overall treatment pathway considerably.

For a detailed patient guide to DMEK, see DMEK Corneal Transplant Surgery — What Patients Need to Know on drmacintyre.com. An overview of all corneal surgery options is at corneaeyedoctor.com/corneal-surgery/.

Consultations for Fuchs dystrophy and DMEK are available at Northern Eye Consultants, Suite 5, Northpark Private Hospital, 135 Plenty Road, Bundoora, and at Bass Coast Eye Centre, Wonthaggi. To book or refer, call (03) 9466 8822 or use HealthLink EDI nthneyec.